Jodar, Esteban http://orcid.org/0000-0002-1234-8560
Campusano, Claudia http://orcid.org/0000-0001-5483-9301
de Jongh, Renate T. http://orcid.org/0000-0001-8414-3938
Holick, Michael F. http://orcid.org/0000-0001-6023-9062
Funding for this research was provided by:
FAES FARMA
Article History
Received: 23 May 2022
Accepted: 31 January 2023
First Online: 2 March 2023
Declarations
:
: Esteban Jodar reports grants from Amgen, AstraZeneca, Boehringer Ingelheim, FAES, Janssen, Lilly, MSD, Novo Nordisk, Pfizer, Sanofi, Shire, and UCB; personal fees from Adium, Amgen, Asofarma, AstraZeneca, FAES, Helios-Fresenius, Italfármaco, Lilly, MSD, Mundipharma, Novo Nordisk, UCB, and Viatris. Claudia Campusano Montaño has received honoraria from Amgen, FAES, Novartis, Sanofi, and Tecnofarma. Renata T de Jongh has received a grant from the Dutch Lung Foundation (project number 5113033), an investigator fee from Shire for a pharmacy-initiated study (SHP634-401), and personal fees from Kyowa Kirin, Lilly and UCB. Michael F. Holick has served as consultant for Biogena Inc., Ontometrics Inc. and Solius Inc.; has received grants from Carbogen Amcis BV and Solius Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
: Not applicable.
: Not applicable.
: Not applicable.
Free to read: This content has been made available to all.